Welcome to our dedicated page for Pmv Pharmaceuticals SEC filings (Ticker: PMVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PMV Pharmaceuticals, Inc. (PMVP) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as a Nasdaq Global Select Market registrant. PMV Pharma is a clinical-stage precision oncology company focused on small molecule, tumor-agnostic therapies targeting p53, and its filings offer detailed insight into both financial condition and clinical development activities.
Investors can review current reports on Form 8-K that PMV Pharma files to announce material events. Recent 8-K filings reference press releases for quarterly financial results, including operating expenses, net loss, and cash, cash equivalents, and marketable securities, as well as corporate updates on the PYNNACLE Phase 1/2 trial of rezatapopt (PC14586). Other 8-Ks incorporate investor presentation materials and press releases describing interim Phase 2 data from PYNNACLE and related safe harbor statements.
Alongside 8-Ks, users can access the company’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which are cited in PMV Pharma’s press releases as containing detailed risk factors, financial statements, and discussion of its clinical programs. These periodic reports are central for understanding research and development spending, general and administrative costs, and the company’s assessment of its cash runway as a clinical-stage entity.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, such as major changes in operating expenses, updates on the PYNNACLE trial, and references to regulatory designations like FDA Fast Track for rezatapopt. Users can also monitor sections related to potential future New Drug Application plans and other regulatory milestones as they are discussed in SEC filings. This page is a practical starting point for analyzing PMVP’s official disclosures, from financial performance to the status of its precision oncology pipeline.
PMV Pharmaceuticals (PMVP) – Form 4 insider transaction
Chief Financial Officer Michael Carulli disclosed the sale of 28,249 common shares on 01 July 2025 at a weighted-average price of $1.0647 per share. According to the filing, the disposition was made solely to satisfy tax-withholding obligations triggered by the vesting of restricted stock units (RSUs). After the transaction, the executive continues to beneficially own 60,146 shares of PMVP common stock, and no derivative security activity was reported. The sale represents a cash value of roughly $30,000 and leaves the CFO with a meaningful equity stake, limiting the signaling impact for investors.
PMV Pharmaceuticals, Inc. (PMVP) – Form 4 insider transaction
President & CEO David Henry Mack reported a sale of 58,411 common shares on 07/01/2025 at an average price of $1.0645 per share. The sale was executed under Rule S (open-market or private sale) and, according to the filing, was undertaken solely to cover tax obligations arising from the vesting of restricted stock units (Footnote 1).
After the transaction, Mack continues to own 536,133 shares directly. He also has indirect interests of 165,307 shares (Stinson 2021 Irrevocable Trust), 147,915 shares (Mack-Mulligan Revocable Trust) and 56,978 shares (Mack/Mulligan 2020 Irrevocable Descendants’ Trust), bringing his total reported beneficial position to 906,333 shares. No derivative securities were bought or sold, and there were no new options, warrants, or RSU transactions reported.
The sale represents roughly 10.9 % of Mack’s direct holdings and about 6.4 % of his total reported beneficial ownership. Because the disposition was for tax-withholding purposes, it does not necessarily signal a change in sentiment; nevertheless, investors often monitor any CEO share sales for potential insight into insider views of future prospects.